{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ORIC",
  "name": "Oric Pharmaceuticals, Inc.",
  "url": "https://orbyd.app/dossiers/ORIC/",
  "json_url": "https://orbyd.app/dossiers/ORIC.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": "LOW",
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "mCRPC PRC2 story de-risked as rinzimetostat enters registrational Phase 3 (Himalayas-1, 2026-07-14) with Bayer supplying NUBEQA and a J&J-backed enozertinib lung program behind it. But pivotal data is 2028+, so the only near-term mover is undated enozertinib 2H-2026 readouts. Range-bound $7–15 tape; build on weakness, not a breakout chase at $10.73.",
  "invalidation_trigger": "A weekly close below $8.50 gives back the post-Phase-3-initiation advance and re-enters the lower half of the 52-week range; a disappointing enozertinib 2H-2026 readout or a pre-Phase-3 capital raise would confirm the break.",
  "catalyst_date": "2026-08-06",
  "outcome": "PLAYED_OUT",
  "outcome_date": "2026-08-04",
  "invalidation_fired": false,
  "themes": [
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Naming: rinzimetostat = former ORIC-944 (oral PRC2 inhibitor); enozertinib = former ORIC-114 (brain-penetrant EGFR/HER2). News may appear under either name.",
    "Himalayas-1 Phase 3 (initiated 2026-07-14) rPFS reads out ~2028+ — the trial START is not a data catalyst; do not confuse initiation with efficacy.",
    "Balance sheet: $419.7M cash/investments (Q1 2026), runway into 2H 2028, ~$30M/quarter burn; watch for a raise before Phase 3 data.",
    "Q2 2026 earnings ~early August (est.) — confirm exact date before treating as an earnings-window blocker.",
    "Bayer supplies NUBEQA (darolutamide) free with NO rights to rinzimetostat; ORIC keeps full global economics. J&J partners enozertinib with SC amivantamab.",
    "Near-term mover is enozertinib 2H-2026 data (1L EGFR exon 20 mono + SC-amivantamab combo + PACC mono), likely at a fall conference (WCLC/ESMO), outside any 30-day window."
  ],
  "body_markdown": "## Current Thesis\nClinical-stage oncology name whose narrative leg is rinzimetostat (an oral PRC2 inhibitor) graduating from Phase 1b signal to a registrational Phase 3 in metastatic castration-resistant prostate cancer (mCRPC). The Himalayas-1 trial was initiated 2026-07-14 in combination with NUBEQA (darolutamide), with Bayer supplying drug free and taking no rights, while a J&J-backed enozertinib lung program sits behind it as second-program optionality. The problem for a momentum book: the pivotal data is a 2028+ event, and the tape is range-bound ($7.23–$14.93). The corporate story is accelerating; the price is consolidating. This is a build-on-weakness or breakout-confirmation biotech, not a clean accelerating chase at $10.73.\n\n## Bull Case\n- **Program de-risked into pivotal (2026-07-14):** Himalayas-1 enrolls ~600 post-abiraterone mCRPC patients, 1:1 randomization, primary endpoint radiographic PFS, key secondary overall survival, RP3D 400 mg once daily, across 250+ sites in 25 countries. Rinzimetostat moved from dose-exploration to registrational.\n- **Bayer validation, zero economics given up (2026-07-14):** Bayer provides darolutamide at no cost and receives no license, option, or rights to rinzimetostat; ORIC keeps full global development and commercial rights. Big-pharma endorsement of the combo without dilution of the asset.\n- **Second validated shot on goal:** enozertinib (brain-penetrant EGFR/HER2 inhibitor) carries a J&J collaboration to combine with subcutaneous amivantamab in 1L EGFR exon 20 NSCLC — a second program with a second major partner.\n- **Funded past the readouts:** $419.7M cash and investments (Q1 2026), runway into 2H 2028, burn ~$30M/quarter. Financing risk is low through the enozertinib data and into Phase 3 enrollment.\n- **Sell-side lopsided long:** Strong Buy, ~14 buy / 1 hold / 0 sell, average price target ~$20–22 (range $15–25) vs the 2026-07-17 close of $10.73 — roughly 90% implied upside if data cooperates.\n\n## Bear Case\n- **The catalyst just spent itself:** Himalayas-1 is a trial START, not a result. RPFS on a 600-patient PFS/OS design reads out around 2028; the 2026-07-14 initiation is the type of press-release event that pulls forward buyers and then leaves a multi-year data gap — classic dead-money risk after the pop.\n- **Mechanism unproven at scale:** Phase 1b \"best-in-class properties\" (half-life ~20h, target engagement, clean safety) is early-signal, not randomized efficacy. PRC2 inhibition has no approved precedent in mCRPC; the binary is genuine.\n- **No technical confirmation:** $10.73 sits mid the 52-week $7.23–$14.93 band, ~28% below the high. The market-cap pop to ~$1.11B was a news reaction, not a breakout through range resistance.\n- **Structural cash burner:** -$135M net loss, -$1.40 EPS, ~$30M/quarter. Runway to 2H 2028 makes a raise plausible before Phase 3 data — a dilution overhang that tends to appear right after the stock runs.\n- **Crowded lung field:** enozertinib competes in EGFR exon 20 / atypical NSCLC against amivantamab and others; it has to differentiate on CNS penetration and tolerability to move the needle.\n\n## Setup & Price Structure\n- Last $10.73 (2026-07-17 close); market cap ~$1.11B, 103.5M shares outstanding.\n- 52-week range $7.23–$14.93 — current print mid-range, ~48% above the low, ~28% below the high.\n- Recent action: market cap up ~28.5% over the reference window on the Phase 3 initiation and Bayer news, a corporate-progress move rather than a volume breakout above the range high.\n- No accelerating structure to buy: the name is consolidating inside a wide band. A momentum entry wants one of two things — a volume reclaim toward the $14–15 high ahead of the 2H enozertinib data, or a pullback to the $7–8 base to buy the multi-year optionality cheap.\n- No dated binary inside 30 days, so the tape can drift and time-decay a fresh position.\n\n## Catalyst Calendar (next 30 days)\n\n- **2H 2026 (undated, likely a fall conference — WCLC ~September / ESMO ~mid-October):** enozertinib 1L EGFR exon 20 monotherapy, the subcutaneous-amivantamab combination, and 1L EGFR PACC monotherapy data. This is the real near-term mover and it sits outside the 30-day window.\n- **Himalayas-1 rinzimetostat rPFS:** multi-year (~2028+). Not a 2026 catalyst; do not model it as one.\n\n## Elapsed catalysts\n\n- **~2026-08-06 (est.):** Q2 2026 earnings and cash update. Soft catalyst — watch for reaffirmed runway (into 2H 2028) and confirmation of enozertinib readout timing, not a data event. Confirm the exact date before treating it as an earnings-window blocker. *(passed 3d ago)*\n\n## What Would Change Our Mind\n- **Bull-invalidation (price):** a weekly close below $8.50 gives back the post-Phase-3-initiation advance and drops the tape into the lower half of the 52-week range, signalling the corporate-progress leg failed to hold a bid and the name is dead money until data.\n- **Second condition:** a disappointing enozertinib 2H-2026 readout (no differentiation versus amivantamab, weak 1L EGFR exon 20 response, or thin CNS activity) removes the only near-term catalyst and guts the second-program optionality.\n- **Overhang confirmed:** a capital raise announced before Phase 3 data validates the dilution risk.\n- **Bull-confirmation:** a weekly close reclaiming the $14–15 range high on volume — ideally into positive enozertinib data — flips this from range-bound to a momentum vehicle worth real sizing.\n\n## Correlation Notes\n- Small/mid-cap clinical oncology beta: moves with XBI and biotech risk appetite, and with rate expectations given it is a long-duration, no-cash-flow asset. Broad biotech drawdowns hit unprofitable pipeline names hardest regardless of program quality.\n- mCRPC read-through: sentiment travels with prostate-cancer peers (AR-pathway, PARP, PSMA) and epigenetics/PRC2 plays; a competitor's mCRPC data can reprice the addressable setting for rinzimetostat.\n- EGFR NSCLC read-through: enozertinib is levered to amivantamab (J&J) sentiment and the broader EGFR exon 20 / atypical field; partner data cuts both ways.\n- Idiosyncratic dominance: on trial-data days ORIC decouples from the theme and trades its own binary — correlation collapses when the catalyst is company-specific.",
  "first_seen": "2026-07-15",
  "last_analyzed": "2026-07-18T07:28:03+00:00",
  "last_synthesized": "2026-07-18",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}